Zimbabwe's approval of the long-acting cabotegravir (CAB-LA) for use by HIV-negative people to reduce the risk of getting HIV could pave the way for effective options for HIV prevention, experts say.
Zimbabwe is first country in Africa to announce regulatory approval for long-acting injectable cabotegravir for HIV prevention miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.